Skip to main content
OpenTrials
Completed

NCT Number: NCT04131972

REGENERA Implant in Excised Non-Malignant Breast Lesions

The purpose of this First-in-Human pilot study is to evaluate the safety and performance of REGENERA breast implant in a selected cohort of patients with non- malignant breast lesions treated with excision or lumpectomy in whom the tissue removed is replaced by REGENERA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Benign Breast Disease Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cystic Fibrosis Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

20 year–85 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Azienda Ospedaliero Universitaria Pisana

Pisa, 56126, Italy

About this study

This is a pre-market, single center, interventional, open label, non-comparative, pilot first-in-human study on adult female patients with localized non-malignant breast lesion. This study will include an enrollment period of 12 months and 6 months study duration per patient.

The primary objective of this study is to demonstrate the safety profile of a new breast implant (REGENERA) in excision or lumpectomy of non-malignant breast lesions.

The secondary objectives of this study are:

  • To assess the safety of the implant procedure
  • To assess the feasibility of the implant procedure
  • To evaluate the performance of REGENERA breast implant:
  • In replacing the removed tissue
  • In potential interference with current diagnostic standard of care imaging procedures
  • On patient's quality of life and satisfaction
  • On investigator's satisfaction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients aged 20-85 years
  • Patients eligible for excision or lumpectomy, as per current surgical guidelines
  • Volume deficit compatible with an implant volume of 70 cc
  • Adequate hematopoietic functions
  • Good general health and mentally sound
  • Confirmation of non-malignant lesion (B2 and B3) with no discordance between biopsy and radiological imaging
  • Patients able and willing to give written informed consent form

Exclusion criteria

  • Pregnant or breastfeeding women or women who have nursed a child three months within enrolment in the study
  • Non-malignant lesions (B2 and B3) with discordance between biopsy and radiological imaging
  • Infection of the surgical site confirmed pre-operatively by clinical examination
  • Acute or chronic severe renal insufficiency (creatinine values < 180 μmol/L)
  • History of severe asthma or allergies (including to anaesthetics or contrast media)
  • Autoimmune disease
  • Subject with actual concomitant malignancies, lobular neoplasm, metastatic breast carcinoma, sarcoma, malignant phyllodes lesions, or Paget's disease
  • Subject who are known to be carriers of BCRA mutation
  • Inability to undergo MRI or allergy to contrast media
  • Systemic infections in active phase
  • Immunocompromised patients (HIV)
  • Subjects who have participated in another study within the past 3 months
  • Patients who received immunosuppressant therapy in the last 3 months
  • Non-collaborative patients (severe physical disabilities or psychiatric disorders, as per specialist opinion).

Treatment and study plan

REGENERA

Device

REGENERA breast implant

Primary outcomes

  1. Cumulative number of all Serious Adverse Events

    Time frame: at 6 months from implantion of the device

    Cumulative number of Serious Adverse Events collected throughout the study and associated with the REGENERA implant device (Adverse Device Effects)

Secondary outcomes

  1. Measurement of changes in breast appeareance before and after surgery through antropomorphic chest parameters

    Time frame: at 2 weeks before the implantation of the device (Day 0), 1 week from Day 0, 3 months from Day 0, 6 months from Day 0

    Assess breast appearance before and after surgery with photo and chest measurement. In particular, the following measures, in cm, will be evaluated: sternal notch to nipple (SN), nipple to inframammary fold (NF), nipple to sternum (NM), the areola diameter and the ptosis grade.

  2. Measurement of the reduction of reliability of the currently used diagnostic imaging techniques

    Time frame: at 1 week from the implantation of the device (Day 0), 2 weeks from Day 0, 1 month from Day 0, 3 months from Day 0 and 6 months from Day 0

    Assess the potential interference with current, standard- of-care imaging techniques by evaluation of the following factors: (1) for ultrasound, the possible attenuation of the acoustic beam preventing the visualization of the tissue behind the implant; (2) for magnetic resonance imaging, possible creation, caused by the implant, of images mimicking a pre-invasive or invasive lesion.

  3. Patient Quality of Life measured through Breast-Q questionnaire

    Time frame: at 1 month from the implantation of the device (Day 0), 6 months from Day 0 versus 2 weeks before Day 0

    Measure changes in patient's Quality of Life (QoL) and satisfaction through Breast-Q™ questionnaire (pre- and post-operative Breast Conserving Therapy (BCT) module version 2.0) after surgery versus baseline (prior implantation surgery).

    Breast-Q™ questionnaire includes 7 scales measuring (i) breast satisfaction, (ii) psychosocial well-being, (iii) physical breast well-being, (iv) sexual well-being, (v) patient experience satisfaction with the surgeon, (vi) patient experience satisfaction with the medical equip and (vii) patient experience satisfaction with the hospital staff. Each scale is evaluated by defined questions where the patient has to answer by a numeric scale. For example: "1", "non of the time"; "2", "a little of the time"; "3", some of the time; "4", "most of the time"; "5", "all of the time". Once the questions are answered, a conversion table is applied to convert the raw scale summed score into a score from 0 (worst) to 100 (best).

  4. Patient pain measurement through a Visual Analogue Scale

    Time frame: at 2 weeks before the implantation of the device (Day 0), Day 0, 1 week from Day 0, 2 weeks from Day 0, 1 month from Day 0, 3 months from Day 0 and 6 months from Day 0

    Assess pain intensity with a Visual Analogue Scale (VAS) at each study visit. The VAS measure will be made through a cross (X) that the patient has to put along a bar. The left margin of the bar corresponds to "no pain" (0 score) and the right margin to "worst pain" (10 score).

  5. Measure of the Investigator's satisfaction on the implantation procedure, through a Visual Analogue Scale (VAS) and an ad-hoc questionnaire

    Time frame: implantation satisfaction (VAS + ad-hoc questionnaire) at the implantation of the device (Day 0) and REGENERA performance (VAS) at 6 months from Day 0

    Assess investigator's satisfaction on the implantation procedure, through a Visual Analogue Scale (VAS) and an ad-hoc questionnaire (developed by the Sponsor), and on the REGENERA performance, through a VAS scale.

    The VAS measure will be made through a cross (X) that the patient has to put along a bar. The left margin of the bar corresponds to "no pain" (0 score) and the right margin to "worst pain" (10 score).

    The ad-hoc questionnaire has a unique scale made of 5 levels (1 corresponds to "strongly disagree" and 5 corresponds to "strongly agree") to be used for each question. As there are 12 questions, 12 is the minimum score and 60 is the maximum score as a sum of all answers.

  6. Cumulative number of all Adverse Events associated with the surgical procedure

    Time frame: at 6 months from the implantation of the device

    Cumulative number of all Adverse Events associated with the surgical procedure: number of re-operations and / or explants due to seroma, hematoma, infection, wound dehiscence, skin retraction, acute inflammatory reactions, allergic reactions to the device, persistent pain.

Sponsors and collaborators

Lead sponsor

Tensive SRL

Industry

Registry information

Official study title

A Pilot Study of REGENERA Implant in Localized Non- Malignant Breast Lesions Treated by Excision or Lumpectomy

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Oct 18, 2019
Registry last updated
Feb 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.